Search research articles
Contact Us
Filters
Showing results (101-110 of 135) with videos related to
Page
of 14
Sort By:
Blood Advances
|
November 8, 2019
Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B
Annette Von Drygalski, Adam Giermasz, Giancarlo Castaman, et al.
The Lancet. Haematology
|
March 4, 2024
Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial
Michiel Coppens, Steven W Pipe, Wolfgang Miesbach, et al.
Bioelectronic Medicine
|
April 3, 2026
A novel transcutaneous auricular neurostimulation electrode configuration for treatment of heavy menstrual bleeding: an open-label trial
Christopher J Czura, Angela C Weyand, Maureen K Baldwin, et al.
American Journal of Hematology
|
May 2, 2020
The impact of extended half-life factor concentrates on prophylaxis for severe hemophilia in the United States
Lynn M Malec, Dunlei Cheng, Char M Witmer, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
October 9, 2018
Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multi-centre, non-interventional study
Johnny Mahlangu, Johannes Oldenburg, Michael U Callaghan, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
November 12, 2025
Safety and Effectiveness of Emicizumab in People With Haemophilia A Enrolled in the ATHN 7 Haemophilia Natural History Study
Tyler W Buckner, Shannon L Carpenter, Nabil Daoud, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
July 26, 2021
Patient preferences and priorities for haemophilia gene therapy in the US: A discrete choice experiment
Michelle Witkop, George Morgan, Jamie O'Hara, et al.
The New England Journal of Medicine
|
December 8, 2025
Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B
Steven W Pipe, Wolfgang Miesbach, Michael Recht, et al.
Molecular Therapy. Methods & Clinical Development
|
September 19, 2025
Natural history of preexisting AAV5 antibodies in adults with hemophilia B during the lead-in of the etranacogene dezaparvovec phase 3 study
Robert Klamroth, Michael Recht, Nigel S Key, et al.
Blood Advances
|
April 6, 2025
Completion of Phase 2b trial of etranacogene dezaparvovec gene therapy in patients with hemophilia B over 5 years
Annette von Drygalski, Esteban Gomez, Adam Giermasz, et al.
Page
of 14
Search research articles
Search
Showing results (101-110 of 135) with videos related to
Sort By:
Page
of 14
Blood Advances
|
November 8, 2019
Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B
Annette Von Drygalski, Adam Giermasz, Giancarlo Castaman, et al.
The Lancet. Haematology
|
March 4, 2024
Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial
Michiel Coppens, Steven W Pipe, Wolfgang Miesbach, et al.
Bioelectronic Medicine
|
April 3, 2026
A novel transcutaneous auricular neurostimulation electrode configuration for treatment of heavy menstrual bleeding: an open-label trial
Christopher J Czura, Angela C Weyand, Maureen K Baldwin, et al.
American Journal of Hematology
|
May 2, 2020
The impact of extended half-life factor concentrates on prophylaxis for severe hemophilia in the United States
Lynn M Malec, Dunlei Cheng, Char M Witmer, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
October 9, 2018
Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multi-centre, non-interventional study
Johnny Mahlangu, Johannes Oldenburg, Michael U Callaghan, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
November 12, 2025
Safety and Effectiveness of Emicizumab in People With Haemophilia A Enrolled in the ATHN 7 Haemophilia Natural History Study
Tyler W Buckner, Shannon L Carpenter, Nabil Daoud, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
July 26, 2021
Patient preferences and priorities for haemophilia gene therapy in the US: A discrete choice experiment
Michelle Witkop, George Morgan, Jamie O'Hara, et al.
The New England Journal of Medicine
|
December 8, 2025
Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B
Steven W Pipe, Wolfgang Miesbach, Michael Recht, et al.
Molecular Therapy. Methods & Clinical Development
|
September 19, 2025
Natural history of preexisting AAV5 antibodies in adults with hemophilia B during the lead-in of the etranacogene dezaparvovec phase 3 study
Robert Klamroth, Michael Recht, Nigel S Key, et al.
Blood Advances
|
April 6, 2025
Completion of Phase 2b trial of etranacogene dezaparvovec gene therapy in patients with hemophilia B over 5 years
Annette von Drygalski, Esteban Gomez, Adam Giermasz, et al.
Page
of 14